Sana Biotechnology, Inc. (SANA) - Dilution Analysis

10-Q filing | 276.9M shares outstanding

8-K filing: Sana Biotechnology, Inc. entered into a stock purchase agreement with Mayo Clinic to sell 7,507,507 shares of common stock at $3.33 per share, for gross proceeds of approximately $25.0 million, with a potential for an additional 7,507,507 shares at the same price if elected by Mayo Clinic. ($50.0M proceeds)

10-Q filing | 260.5M shares outstanding

10-Q filing | 238.4M shares outstanding

8-K filing: Sana Biotechnology entered into a sales agreement with TD Securities (USA) LLC to sell up to $119.0 million of common stock through an at-the-market offering program, and terminated its prior sales agreement with TD Cowen under which approximately 4.9 million shares were sold for gross proceeds of approximately $30.6 million. ($30.6M proceeds)

10-Q filing | 237.6M shares outstanding

POS AM filing: Sana Biotechnology, Inc. files a POS AM for a mixed shelf offering of common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts and units, with an aggregate offering price not to exceed $350,000,000.

10-K filing | 230.9M shares outstanding

10-Q filing | 235.4M shares outstanding

10-Q filing | 234.4M shares outstanding

10-Q filing | 217.3M shares outstanding

10-K filing | 220.4M shares outstanding

10-Q filing | 197.0M shares outstanding

10-Q filing | 192.5M shares outstanding

10-Q filing | 191.2M shares outstanding

POS AM filing: Sana Biotechnology, Inc. may offer and sell up to $350,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings.

10-K filing | 188.3M shares outstanding

10-Q filing | 189.3M shares outstanding

10-Q filing | 187.6M shares outstanding

10-Q filing | 189.7M shares outstanding

10-K filing | 189.5M shares outstanding

10-Q filing | 188.8M shares outstanding

10-Q filing | 190.5M shares outstanding

10-Q filing | 187.7M shares outstanding

S-1/A filing: This S-1/A filing is for an initial public offering of common stock.

S-1/A filing: This S-1/A filing details an offering of common stock with an underwriters' over-allotment option. The company intends to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, to fund the ongoing development of our _in vivo_ cell engineering platform and product candidates, which we anticipate will allow us to complete preclinical studies on each of our current product candidates and advance at least three _in vivo_ product candidates through human proof of concept studies; to fund the ongoing development of our _ex vivo_ cell engineering platform and product candidates, which we believe will allow us to complete preclinical studies on each of our current product candidates and advance at least three _ex vivo_ product candidates through human proof of concept studies; to fund research efforts focused on advancing and broadening the scope of our _ex vivo_ and _in vivo_ cell engineering platforms; to continue developing manufacturing capabilities for our product candidates; and the remainder, if any, for working capital and other general corporate purposes.

S-1/A filing: This S-1/A filing includes information on a common stock offering of 15,000,000 shares with an underwriter's over-allotment option of 2,250,000 shares, resulting in 175,314,776 to 177,564,776 shares outstanding after the offering.

S-1 filing: This is an S-1 filing for an initial public offering of common stock.